| Abstract | Valvularne bolesti srca, pored koronarne bolesti te srčanog zatajenja, najčešće sukardiovaskularne bolesti, a među njima prednjači aortna stenoza (AS). Jedina učinkovita metoda liječenja je zamjena aortnog zalistka. Kirurška zamjena aortnog zaliska (engl.. Surgical Aortic Valve Replacement - SAVR) desetljećima je standard u liječenju bolesnika. Manje invazivna opcija u liječenju starijih, visokorizičnih te inoperabilnih bolesnika sa simptomatskom teškom AS nedvojbeno je TAVR metoda. Glavni cilj ove studije bio je analizirati postiže li se transkateterskom metodom liječenja bolesti aortnog zaliska niža stopa komplikacija povezanih s krvarenjem i kraće trajanje hospitalizacije u odnosu na otvoreni kirurški pristup.
U ovoj studiji bila su uključena 164 ispitanika, u razdoblju od 01.01.2022. do 31.12.2022. godine, a kod kojih je učinjena zamjena aortnog zaliska TAVR ili SAVR metodom. Istraživanje je provedenu u Kliničkom bolničkom centru Rijeka. Glavni uključujući kriteriji bili su: dijagnoza aortna stenoza (šifra I35.0), aortna insuficijencija (šifra I35.1), aortna stenoza s insuficijencijom (šifra I35.2) te primjena TAVR ili SAVR metode liječenja. Transkateterska metoda liječenja aortnog zaliska, a obzirom na skupinu ispitanika visokorizičnih zdravstvenih čimbenika generira brži oporavak, odnosno kraću duljinu hospitalizacije i značajno manju potrebu za transfuzijom krvi uz nižu stopu smrtnosti. Kirurška metoda liječenja aortnog zaliska, generirala je rezultate značajno duljeg trajanja hospitalizacije, praćena većim stopama krvarenja i primjenom transfuzije krvi uz višu stopu smrtnosti. |
| Abstract (english) | Valvular heart diseases, alongside coronary artery disease and heart failure, are among the most common cardiovascular diseases, with aortic stenosis (AS) leading among them. The only effective treatment method is aortic valve replacement. Surgical Aortic Valve Replacement (SAVR) has been the standard treatment for decades. Transcatheter Aortic Valve Replacement (TAVR) has become the standard, less invasive option for treating elderly, high-risk, and inoperable patients with symptomatic severe AS. The main objective of this study was to analyse whether the transcatheter treatment method achieves a lower rate of bleeding-related complications and shorter hospitalisation duration compared to the open surgical approach in treating aortic valve disease. This study included 164 subjects from January 1, 2022, to December 31, 2022, who underwent aortic valve replacement using either TAVR or SAVR. The research was conducted at the Clinical Hospital Center Rijeka. The main inclusion criteria were a diagnosis of aortic stenosis (code I35.0), aortic insufficiency (code I35.1), aortic stenosis with insufficiency (code I35.2), and the application of TAVR or SAVR treatment. The transcatheter treatment method for the aortic valve, considering the group of high-risk subjects, results in faster recovery, shorter hospitalisation length, significantly reduced need for blood transfusion, and lower mortality rate. The surgical treatment method for the aortic valve generates significantly longer hospitalisation duration, accompanied by higher rates of bleeding, blood transfusion, and a higher mortality rate. |
